Get the Stockscreener App
31.11
0.81%
0.25
Indivior Pharmaceuticals Inc stock is traded at $31.11, with a volume of 13.58M.
It is up +0.81% in the last 24 hours and down -10.03% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$30.86
Open:
$30.98
24h Volume:
13.58M
Relative Volume:
5.14
Market Cap:
$3.89B
Revenue:
$1.24B
Net Income/Loss:
$209.00M
P/E Ratio:
18.74
EPS:
1.6605
Net Cash Flow:
$-94.86M
1W Performance:
-3.59%
1M Performance:
-10.03%
6M Performance:
+34.04%
1Y Performance:
+224.40%
1-Day Range:
$30.47
$32.18
1-Week Range:
$29.40
$35.34
52-Week Range:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
31.11 | 3.89B | 1.24B | 209.00M | -94.86M | 1.6605 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 221% One Year Surge? - simplywall.st
Indivior director Kingsley buys $29,953 in shares By Investing.com - Investing.com Nigeria
Insider Buying: Barbara Ryan Acquires Shares of Indivior Pharmac - GuruFocus
Indivior Pharmaceuticals prices upsized $450M convertible senior notes - MSN
Indivior PLC Stock (ISIN: US45580R1068) Drops 6% as $450M Convertible Notes Offering Signals Capital - AD HOC NEWS
Indivior Prices Upsized Convertible Notes for Debt Refinancing - TipRanks
Indivior (INDV) Upsizes Convertible Notes Offering to $450M - GuruFocus
Indivior plans $400 million convertible notes offering By Investing.com - Investing.com India
Indivior Announces Proposed Convertible Senior Notes Offering - Sahm
Indivior Prices $450 Million Convertible Senior Notes Offering - National Today
Indivior (INDV) Plans $400 Million Convertible Notes Offering - GuruFocus
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - The Manila Times
Indivior prices $450 million convertible notes offering - Investing.com
Indivior Pharmaceuticals Announces Pricing of $450 Million Convertible Senior Notes Offering - Quiver Quantitative
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
Indivior plans $400 million convertible notes offering - Investing.com Nigeria
Indivior proposes $400M convertible senior notes due 2031 to refinance debt, fund buybacks - TradingView
Indivior plans $400M convertible senior notes offering - MSN
Indivior Announces $400 Million Convertible Notes and Buyback - TipRanks
Indivior stock falls after convertible notes offering announced - Investing.com
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares - MarketBeat
Indivior director Kingsley buys $29,953 in shares - Investing.com
Indivior (INDV) Study: Sublocade Reduces Healthcare Costs for OU - GuruFocus
New Study Shows Adherence to Monthly Injectable - GlobeNewswire
Ryan Barbara buys Indivior (INDV) shares worth $1,009 - Investing.com South Africa
Ryan Barbara buys Indivior (INDV) shares worth $1,009 By Investing.com - Investing.com Nigeria
Victory Capital Management Inc. Makes New $19.44 Million Investment in Indivior PLC $INDV - MarketBeat
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Earnings Growth And New US$400 Million Buyback - Sahm
Claret Asset Management Corp Has $18.92 Million Stake in Indivior PLC $INDV - MarketBeat
Implied Volatility Spikes for Indivior Pharmaceuticals Equity Options - Bitget
Implied Volatility Surging for Indivior Pharmaceuticals Stock Options - TradingView
Jefferies Financial Group Inc. Has $17.05 Million Stock Holdings in Indivior PLC $INDV - MarketBeat
How Strong Q4 Results, Reaffirmed 2026 Outlook and New Buyback At Indivior (INDV) Has Changed Its Investment Story - Sahm
Indivior (INDV) Q4 2025 Earnings Call Transcript - AOL.com
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its Recent Pullback In Price? - simplywall.st
Vanguard Group Inc. Has $83.10 Million Holdings in Indivior PLC $INDV - MarketBeat
Indivior (INDV) CAO reports stock unit vesting and tax-withholding share disposals - Stock Titan
Indivior (INDV) CFO equity awards vest; shares withheld for taxes - Stock Titan
Global Transdermal Skin Patch Market Size, Growth, Trends & - openPR.com
Royce & Associates LP Buys Shares of 246,524 Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Indivior Pharmaceuticals, Inc. (INDV): Investor Outlook With 45% Potential Upside - DirectorsTalk Interviews
Quantbot Technologies LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Equities Analysts Issue Forecasts for Indivior Q4 Earnings - MarketBeat
HC Wainwright Issues Negative Forecast for Indivior Earnings - MarketBeat
Indivior Pharmaceuticals (INDV) Valuation Check After Strong Long Term Shareholder Returns - Sahm
Indivior’s Strong 2025 Results and US$400 Million Buyback Might Change The Case For Investing In Indivior Pharmaceuticals (INDV) - simplywall.st
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT I - GuruFocus
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change - Yahoo Finance
Indivior Pharmaceuticals, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
3.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):